Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Astellas Pharma

Here's Why Embattled Apellis Stock, A Former Highflier, Just Took Another Hit To The Chin

Astellas Pharma won FDA approval for a rival to Apellis Pharmaceuticals' eye-disease treatment and APLS stock plunged Monday.

Investors Business Daily

Biotech Buying Bonanza: Iveric Bio Snags $5.9 Billion Deal From Astellas Pharma

Astellas Pharma snapped up Iveric Bio for $5.9 billion in cash, the companies said Monday in an announcement that sent ISEE stock flying.

Investors Business Daily

Japan PM demands release of businessman detained in China

Japan's Prime Minister Fumio Kishida said on Monday the government would continue to strongly demand that Beijing releases an Astellas Pharma employee detained in China, as fears remain over the safety of China's business environment.

Reuters

From analysis to the latest developments in health,
read the most diverse news in one place.

Japan foreign minister Hayashi to visit Beijing on Saturday

Japan Foreign Minister Yoshimasa Hayashi said on Friday he will visit Beijing for two days from Saturday to discuss a range of issues, including the detention of an Astellas Pharma Inc employee.

Reuters

Japanese man detained in China is Astellas Pharma employee - Kyodo

A Japanese man detained in China this month is a senior official of Astellas Pharma Inc, Kyodo news agency reported on Sunday citing a company spokesperson.

Reuters

Recap Of Tuesday's Biotech Catalysts - End of The Day Summary

European Commission (EC) has approved AbbVie’s (NYSE:ABBV) lead asset RINVOQ (upadacitinib 45 mg [induction dose] and 15 mg and 30 mg [maintenance doses]) for the treatment of adult patients with moderately to severely active ulcerative colitis. AbbVie shares traded in a range of $150.33 to $153.56 on a day volume…

Benzinga

Astellas' Menopause Drug Suffers Setback After Failed Asian Trial

After acing a pair of phase 3 trials, Astellas Pharma Inc (OTC:ALPMF) has reported the failure of fezolinetant to beat placebo in a late-stage study of patients in Asia. The study randomized 302 women in China, Korea, and Taiwan. After 12 weeks, Astellas saw numerical improvements in the rate of hot flashes from baseline…

Benzinga

Read news from The Economist, FT, and more,
with one subscription

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Apellis Pharmaceuticals

26 stories

Astellas Pharma Inc

23 stories

Medicines and Healthcare products Regulatory Agency

Global Blood rapeutics

14 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Amyotrophic lateral sclerosis

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.